Lawrence Lum

6PUBLICATIONS
27CO-AUTHORS
Tumour immunologyMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Aug 12, 2025
LAG3+ CD8+ T cell subset drives HR+/HER2- breast cancer reduction in bispecific antibody armed activated T cell therapy.

Robert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu

|Jul 14, 2025
LAG3+ CD8+ T cell Subset Drives HR+/HER2- Breast Cancer Reduction in Bispecific Antibody Armed Activated T Cell Therapy.

Robert Weldon Barnes, Archana Thakur, Suna Onengut-Gumuscu

|Jan 28, 2025
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma.

Binod Dhakal, Parameswaran Hari, Saurabh Chhabra

|Sep 25, 2024
Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T.

Michael C Brown, Vincent M D'Anniballe, David Boczkowski

|Oct 18, 2022
Phase II Trial of Pembrolizumab and Anti-CD3 x Anti-HER2 Bispecific Antibody-Armed Activated T Cells in Metastatic Castration-Resistant Prostate Cancer.

Ulka N Vaishampayan, Archana Thakur, Wei Chen

|Jun 12, 2021
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer.

Lawrence G Lum, Zaid Al-Kadhimi, Abhinav Deol

Pageof 1

Frequent Collaborators

4 joint publications

Archana Thakur

2 joint publications

Wei Chen

2 joint publications

Sepideh Dolatshahi

2 joint publications

Suna Onengut-Gumuscu